Feasibility, safety, and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional pre-clinical safety end points failed to predict 6-month clinical angiographic results.

MLA

Ormiston, John A., et al. “Feasibility, Safety, and Efficacy of a Novel Polymeric Pimecrolimus-Eluting Stent: Traditional Pre-Clinical Safety End Points Failed to Predict 6-Month Clinical Angiographic Results.” JACC. Cardiovascular Interventions, vol. 2, no. 10, Oct. 2009, pp. 1017–24. EBSCOhost, https://doi.org/10.1016/j.jcin.2009.08.006.

APA

Ormiston, J. A., Webster, M. W. I., Schwartz, R. S., Gladding, P., Stewart, J. T., Kay, I. P., Ruygrok, P. N., & Hatrick, R. (2009). Feasibility, safety, and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional pre-clinical safety end points failed to predict 6-month clinical angiographic results. JACC. Cardiovascular Interventions, 2(10), 1017–1024. https://doi.org/10.1016/j.jcin.2009.08.006

Chicago

Ormiston, John A, Mark W I Webster, Robert S Schwartz, Patrick Gladding, James T Stewart, I Patrick Kay, Peter N Ruygrok, and Robert Hatrick. 2009. “Feasibility, Safety, and Efficacy of a Novel Polymeric Pimecrolimus-Eluting Stent: Traditional Pre-Clinical Safety End Points Failed to Predict 6-Month Clinical Angiographic Results.” JACC. Cardiovascular Interventions 2 (10): 1017–24. doi:10.1016/j.jcin.2009.08.006.